CBN and CBG: how do they differ from CBD?

First CBD, then suddenly CBN and CBG on the same shelf, each with a sleepy, calm or "next-gen" reputation to live up to. The alphabet soup keeps getting longer. So here is a quick tour: what each one is, where it comes from, and how much human research is behind the claims.

Think of them as three cousins rather than one family brand: CBD, CBN and CBG are different molecules, and none is a stand-in for another. CBN forms when THC ages. CBG is the chemical starting point from which the plant makes other cannabinoids. CBN has a handful of small human sleep trials with mixed results. CBG has even fewer, mostly small and mostly neutral or preliminary. The Commission said on 27 February 2023 that no CBD or other cannabinoid had been authorised as a food, and we found no later authorisation for CBN or CBG.

Three cannabinoids, three different stories

• : Where it comes from; CBD: Made directly by the plant (from its acid form); CBN: Forms as THC oxidises with age, heat and light; CBG: Made directly by the plant; its acid form is the precursor of other cannabinoids
• : Intoxicating?; CBD: No; CBN: Little evidence of it in people at studied doses; more on that below; CBG: No intoxication reported in the human trials below
• : Human evidence; CBD: One prescription medicine for rare epilepsies; thinner for anxiety, sleep and pain; CBN: A few small sleep trials, some funded by industry; CBG: A few small trials with mixed or neutral results
• : EU novel food status; CBD: Oral CBD described as unauthorised by EFSA (Feb 2026) and the Commission (27 Feb 2023); CBN: Treated as novel by the Commission (2023); no authorisation found; CBG: Treated as novel by the Commission (2023); no authorisation found

CBN: the one that comes from ageing THC

Cannabinol was the first cannabinoid identified, in 1896. It is an oxidative product of THC, so it builds up in cannabis that has been exposed to air, heat and light, according to the University of Sydney team's 2025 paper. The same paper notes that cannabis folklore holds that aged cannabis is especially sleepy and that CBN is responsible, which is where the "sleepy cannabinoid" tag comes from. Folklore is a fine reason to start asking, but it is a poor reason to stop at the first answer.

That origin has a practical side effect. CBN in products sits close to THC chemically and historically, so the usual questions about trace THC, labelling and testing apply more than they do with some other cannabinoids.

What human research actually exists

The sleep claim has been tested, but not very much, and not very consistently: a handful of small, short trials that point in different directions. Oldest to newest:

A 2021 review found the foundations were thin. Jamie Corroon's narrative review screened 99 human studies and reviewed eight in full. Most were small studies from the 1970s and 1980s. It found no trials that tested CBN against validated sleep questionnaires or sleep-lab recordings at that point, and concluded there was insufficient published evidence for sleep claims. It also noted that marketed products typically contained 5 mg or less, far below what trials would need to test.

A 293-person trial: hints at 20 mg, primary outcome missed. In a randomised, placebo-controlled trial of 293 adults aged 18 to 55 who rated their sleep as poor, people took 20 mg of CBN, or CBN combined with 10, 20 or 100 mg of CBD, or placebo, for seven nights. The main outcome, sleep quality, did not reach statistical significance for CBN alone (odds ratio 2.26, 95% CI 0.93 to 5.52). Fewer awakenings and lower overall sleep disturbance did reach significance. Time to fall asleep, time awake after falling asleep and daytime tiredness did not differ from placebo, and adding CBD did not improve the result. Canopy Growth, a cannabis company, funded the trial.

A 2024 trial of a branded CBN product reported benefits at 25, 50 and 100 mg. In a trial of just over 1,000 people, doses of 25, 50 or 100 mg of a hemp-derived CBN formulation, 4 mg of melatonin and placebo were compared on a sleep-disturbance questionnaire. Every group, including the melatonin group, improved more than the placebo group, and the CBN groups did not differ from the melatonin group. The company whose proprietary formulation was tested, Floraworks, is listed as funder. It measured sleep quality by questionnaire rather than by sleep-lab recording, and the sponsor owns the formulation tested.

A 2026 trial in diagnosed insomnia disorder gave the cleanest, and most cautious, answer. Researchers at the Woolcock Institute and the University of Sydney ran a single-night crossover trial in 20 adults with physician-diagnosed insomnia disorder, giving 30 mg or 300 mg of CBN isolate, or placebo, two hours before bedtime. The main outcome, how long people were awake after falling asleep, did not improve at either dose. At 300 mg, sleep-onset time fell by about seven minutes, light sleep (stage N2) increased by 3.8% and participants rated their sleep quality higher (these were secondary outcomes). Side effects were mild overall, but people noticed modest subjective drug effects at 300 mg, and the next morning 300 mg lengthened reaction time on a vigilance test and subtly changed simulated driving control (the authors note this does not necessarily mean impaired driving, but they advise caution about next-day impairment with high doses, especially for driving). The authors wrote that the trial does not provide direct evidence that CBN is effective for insomnia in routine clinical care, and called for larger, repeated-dosing trials. It was funded by the Lambert Initiative, a philanthropically funded cannabinoid research centre at the University of Sydney.

A 2025 pilot used a combination product, so it cannot speak for CBN. A small crossover pilot of 20 adults with subthreshold insomnia symptoms tested a soft gel containing 3 mg THC, 6 mg CBN, 10 mg CBD and terpenes for ten days. Participants improved on several questionnaires, but because THC was part of the mix, the effect cannot be attributed to CBN.

And then there are rats. A 2025 paper found that CBN increased total sleep time in rats, with an initial dip before the rise, and that its main metabolite, 11-hydroxy-CBN, reached equally high brain levels and was itself active. The metabolite finding suggests that what happens after a dose may not come from CBN alone. It is an animal finding, though, and says nothing yet about people.

Putting it together

There is something worth studying here. In people, the findings so far are small, mostly short, and use a range of doses (20 to 300 mg across the trials above). Some positive results came from trials with industry funding, and the one trial in diagnosed insomnia missed its primary outcome. Together they don't show that CBN reliably helps people fall asleep, or that a trial dose predicts what a retail product delivers.

Marketed claims versus what the trials show

• A product page might say: "The sleepy cannabinoid"; What the trials support: A folklore-based label; human data are limited and mixed
• A product page might say: CBN helps you fall asleep faster; What the trials support: Latency unchanged at 20 mg; reduced at 300 mg in one 20-person trial
• A product page might say: CBN reduces night-time waking; What the trials support: Fewer awakenings at 20 mg in one 293-person trial; time awake after sleep onset unchanged in both trials
• A product page might say: CBN plus CBD works better together; What the trials support: In the 293-person trial, adding CBD did not improve the CBN result
• A product page might say: Non-intoxicating; What the trials support: Mild subjective effects reported at 300 mg in one trial

CBG: a precursor with a lot of lab data

Cannabigerol earns its "mother cannabinoid" nickname from chemistry. Its acid form, CBGA, is the precursor from which the plant makes the acid forms of THC, CBD and CBC, and THCA can later oxidise to the acid precursor of CBN, according to a 2024 review of CBG. The review describes CBG as non-psychoactive and summarises a long list of laboratory and animal work on inflammation, pain and neuroprotection, noting that the underlying mechanisms are largely unclear and that whether results translate to humans remains an open question.

In people, there are only a few trials:

• Anxiety and stress, 2024. In a crossover field trial of 34 healthy adults, a single 20 mg dose of hemp-derived CBG reduced anxiety and stress ratings compared with placebo, with no sign of impairment on the tests used. These were healthy volunteers, tested via video call after a single dose, and the funder, CReDO Science, is a company that works with CBG; its CEO is a co-author.
• Sleep in veterans, 2026. In a decentralised trial of 63 veterans with sleep problems, 25 mg then 50 mg of CBG daily over four weeks produced no statistically significant difference from placebo on the main sleep measure. Only 35 completed the study without major protocol deviations. The authors concluded no firm conclusion on efficacy could be made, though CBG was well tolerated.

So the human case for CBG is a small positive anxiety signal in healthy people (one trial) and a neutral result in a sleep trial (another). It is early. No finding yet supports a specific medical use.

Where CBN and CBG stand in the Netherlands and the EU (read on 8 October 2026)

Laws change and differ by country, so treat this as a snapshot and check current rules before buying or crossing a border.

Netherlands. The Opium Act text (version in force from 17 September 2026), read on 8 October 2026, lists THC and the hemp concentrate "hennepolie" on List I, and cannabis plant material and hashish on List II. CBN and CBG are not named on either list (HHC is named, on List I), and we found no official statement on how products containing them are treated, including products with trace THC.

EU novel food rules. A 2023 Commission statement, endorsed at the Standing Committee on Plants, Animals, Food and Feed on 27 February 2023, named CBG and CBN among the cannabinoids in the hemp plant. It said (summarising here) that a history of consumption in the EU before 15 May 1997 "has not been demonstrated for CBD or any other cannabinoids" from the plant, so with the exception of THC they are treated as novel foods, and that no CBD or other cannabinoid had been authorised. The Commission's page of terminated applications includes applications naming cannabigerol, among them one for cannabidiol and cannabigerol closed on 20 June 2024 and one for synthetic cannabigerol closed on 29 July 2024, both without updating the list of authorised novel foods. We found no EFSA opinion on CBN or CBG as a novel food. In short: no authorisation that we found, and primary responsibility for enforcement sits with member states. We didn't search the Union list of authorised novel foods ourselves; the Commission's Novel Food Status Catalogue is the place to check a specific product. None of this says a product is legal or illegal where you live, and other EU countries differ.

Safety: what is known and what isn't

For CBN and CBG we found no regulator safety assessment of the kind EFSA has produced for CBD, and no long-term human data. What the trials above reported: mostly mild side effects over short periods, drowsiness and fatigue among them, and subtle subjective effects at CBN 300 mg. Sleep products are about sedation, so treat anything that might make you drowsy with care around driving.

EFSA's concerns about CBD, from liver effects to reproductive toxicity, are specific to CBD. They do not transfer to CBN or CBG, but nor do the reassuring parts. If you take medication, are pregnant or breastfeeding, or are under 25, treat CBN and CBG as unknown territory and ask a pharmacist; our overview of supplement and drug interactions explains why.

What a brand's range says (supplier information, 8 October 2026)

Everything in this section is what Cibdol's own public pages said on 8 October 2026; we haven't tested the products.

• CBN oil. Cibdol lists a "CBN Oil 5% + CBD 2.5%" in olive oil with hemp extract and terpenes, giving about 500 mg CBN and 250 mg CBD per 10 ml bottle, roughly 2 mg CBN and 1 mg CBD per drop. Its page describes CBN as non-intoxicating and says it forms slowly as THC oxidises in aged hemp material.
• CBG oil. A "CBG Oil 5% + CBD 2.5%" in the same base, with about 500 mg CBG and 250 mg CBD per bottle. The page says certificates show THC at 0.000% (not detected).
• Stay Asleep capsules. Each capsule is listed with 12.5 mg CBN, 12.5 mg CBD, 50 mg hops extract and 167 mg of griffonia extract (30% 5-HTP), and is described as melatonin-free.

Reading these against the research: trial doses are in milligrams, while product labels use percentages and drops, so trial results can't simply be matched to a bottle, and schedules and populations differ too. This describes the supplier's pages, not how any product is classified in a given country. For a combination such as Stay Asleep, the trials above tested CBN alone or with CBD, not CBN together with hops, 5-HTP and other ingredients, so their results cannot be carried across to it. Whether any of these products suits you is a question for a pharmacist, especially if you take medicines.

Taking the tour home

• CBD, CBN and CBG differ in origin and evidence. Do not use one's evidence to support another.
• CBN: a few small trials, mixed results, uncertain dose, and an unresolved question of whether it works beyond placebo.
• CBG: lots of laboratory work, very few human trials, no established use.
• EU novel food status: the Commission's 2023 statement treats them as novel foods, and we found no authorisation.
• If you are mainly after better sleep, the habits in our sleep hygiene guide have more evidence than any minor cannabinoid, and our guide to reading supplement labels will help with the bottle you are holding.

Where to read next

On the legal side:

• Is CBD Legal in Europe? EU Law and the Dutch Position, for how EU novel food status, EFSA's 2 mg figure, THC numbers and the Dutch position fit together.

Written by Smart Supplements with AI assistance from the sources linked in the text. It has not been reviewed by a clinician.

Last updated: 12 October 2026

This article is for informational purposes only and is not intended as medical advice. Always consult a healthcare professional before starting any new supplement, especially if you take prescription medication.